Pathogenesis of diabetic nephropathy

Zemin Cao, Mark E Cooper, Zemin Cao, Mark E Cooper

Abstract

As the increasing prevalence of diabetes reaches epidemic proportions worldwide, diabetic nephropathy and associated end-stage renal failure will be an unavoidable major health burden to not only individuals with diabetes and their families, but also to the health systems both in developed and developing countries. Over the past decade, a large body of research has focused on diabetic nephropathy ranging from studies in molecular signaling, hemodynamic regulation and pharmaceutical intervention to clinical outcomes. It is likely that the pathophysiology of diabetic nephropathy involves a multifactorial interaction between metabolic and hemodynamic factors. Metabolic factors involve glucose-dependent pathways, such as advanced glycation end-products and their receptors. Hemodynamic factors include various vasoactive hormones, such as components of the renin-angiotensin system. It is likely that these metabolic and hemodynamic factors interact through shared molecular and signaling pathways, such as nuclear factor kappa-light-chain-enhancer of activated B cells and protein kinase C with associated reactive oxygen species generation. It is likely that these contributing factors cause pathological damage not only to the glomerulus, in particular podocytes, but also to the tubulointerstitium. Specific inhibitors of the various pathways are now available and these emerging pharmaceutical interventions might have potential implications for the prevention and treatment of diabetic nephropathy. The mainstay of therapy remains the achievement of optimal glycemic and blood pressure control in order to slow the progression of diabetic nephropathy. Agents that interrupt the renin-angiotensin system have been shown to be particularly useful as renoprotective agents in both hypertensive and normotensive type 1 and type 2 diabetic subjects. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2011.00131.x, 2011).

Keywords: Angiotensin converting enzyme 2; Cell division autoantigen 1; Reactive oxygen species.

Figures

Figure 1
Figure 1
Schema of pathogenesis of diabetic nephropathy. The pathogenesis of diabetic nephropathy is likely to be as a result of metabolic and hemodynamic abnormalities, as seen in diabetes, interacting with each other and with various reactive oxygen species‐dependent pathways. Both gene regulation and activation of transcription factors are influenced by the interactions between metabolic stimuli, hemodynamic factors and reactive oxygen species generation in diabetes. The consequences of this molecular activation or inhibition are functional and structural changes leading to the classical hallmarks of diabetic nephropathy. AGE, advanced glycation end‐products; ECM, extracellular protein production; ESRF, end‐stage renal failure; ET, endothelin; GFR, glomerular filtration rate.

References

    1. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213–219
    1. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001; 44: 1957–1972
    1. Tikellis C, Bernardi S, Burns WC. Angiotensin‐converting enzyme 2 is a key modulator of the renin‐angiotensin system in cardiovascular and renal disease. Curr Opin Nephrol Hypertens 2010; 20: 62–68
    1. Burrell LM, Johnston CI, Tikellis C, et al. ACE2, a new regulator of the renin‐angiotensin system. Trends Endocrinol Metab 2004; 15: 166–169
    1. Koitka A, Cooper ME, Thomas MC, et al. Angiotensin converting enzyme 2 in the kidney. Clin Exp Pharmacol Physiol 2008; 35: 420–425
    1. Thomas MC, Pickering RJ, Tsorotes D, et al. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ Res 2010; 107: 888–897
    1. Burrell LM, Risvanis J, Kubota E, et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 2005; 26: 369–375; discussion 322–324.
    1. Tikellis C, Bialkowski K, Pete J, et al. ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes 2008; 57: 1018–1025
    1. Tikellis C, Johnston CI, Forbes JM, et al. Characterization of renal angiotensin‐converting enzyme 2 in diabetic nephropathy. Hypertension 2003; 41: 392–397
    1. Frojdo S, Sjolind L, Parkkonen M, et al. Polymorphisms in the gene encoding angiotensin I converting enzyme 2 and diabetic nephropathy. Diabetologia 2005; 48: 2278–2281
    1. Chai Z, Sarcevic B, Mawson A, et al. SET‐related cell division autoantigen‐1 (CDA1) arrests cell growth. J Biol Chem 2001; 276: 33665–33674
    1. Tu Y, Wu W, Wu T, et al. Antiproliferative autoantigen CDA1 transcriptionally up‐regulates p21(Waf1/Cip1) by activating p53 and MEK/ERK1/2 MAPK pathways. J Biol Chem 2007; 282: 11722–11731
    1. Ito T, Tsukumo S, Suzuki N, et al. A constitutively active arylhydrocarbon receptor induces growth inhibition of jurkat T cells through changes in the expression of genes related to apoptosis and cell cycle arrest. J Biol Chem 2004; 279: 25204–25210
    1. Radke JR, Donald RG, Eibs A, et al. Changes in the expression of human cell division autoantigen‐1 influence Toxoplasma gondii growth and development. PLoS Pathog 2006; 2: e105
    1. Toh BH, Tu Y, Cao Z, et al. Role of cell division autoantigen 1 (CDA1) in cell proliferation and fibrosis. Genes 2010; 1: 335–348
    1. Pham Y, Tu Y, Wu T, et al. Cell division autoantigen 1 plays a profibrotic role by modulating downstream signalling of TGF‐beta in a murine diabetic model of atherosclerosis. Diabetologia 2010; 53: 170–179
    1. Tu Y, Wu T, Dai A, et al. Cell division autoantigen 1 enhances signaling and the profibrotic effects of transforming growth factor‐beta in diabetic nephropathy. Kidney Int 2011; 79: 199–209
    1. Bonnet F, Cooper ME, Kawachi H, et al. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001; 44: 874–877
    1. Bonnet F, Tikellis C, Kawachi H, et al. Nephrin expression in the post‐natal developing kidney in normotensive and hypertensive rats. Clin Exp Hypertens 2002; 24: 371–381
    1. Forbes JM, Bonnet F, Russo LM, et al. Modulation of nephrin in the diabetic kidney: association with systemic hypertension and increasing albuminuria. J Hypertens 2002; 20: 985–992
    1. Cao Z, Bonnet F, Candido R, et al. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol 2002; 13: 1773–1787
    1. Davis BJ, Cao Z, de Gasparo M, et al. Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. J Hypertens 2003; 21: 209–216
    1. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008; 57: 1446–1454
    1. Thallas‐Bonke V, Thorpe SR, Coughlan MT, et al. Inhibition of NADPH oxidase prevents advanced glycation end product‐mediated damage in diabetic nephropathy through a protein kinase C‐alpha‐dependent pathway. Diabetes 2008; 57: 460–469

Source: PubMed

3
Iratkozz fel